Back to News
Market Impact: 0.3
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
Compass Pathways expects to complete the rolling New Drug Application submission for COMP360, its synthetic psilocybin treatment for treatment-resistant depression, in Q4. The company continues to target a potential commercial launch in H1 2027, representing a positive regulatory and commercialization milestone but with material approval and execution risk remaining.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CMPS0.55
More News
- Trump Says US Team Met With Iranians at UNGA
- Paramount will need to release way more movies to make this merger work
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals
- Meta's quick success with Muse puts consumers back in the driver's seat of the AI trade